Xi Tian

6PUBLICATIONS
19CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Cancer geneticsImmunogenetics (incl. genetic immunology)Predictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Sep 11, 2026
Clinical Outcomes, Treatment Patterns, and Molecular Heterogeneity of TFE3-Rearranged Renal Cell Carcinoma: A Multicenter Real-World Study.

|Aug 07, 2026
APOE+ macrophages and POSTN+CAFs form immune-exclusion niche driving immunotherapy resistance in clear-cell renal carcinoma.

|May 17, 2022
Special issue "The advance of solid tumor research in China": Multi-omics analysis based on 1311 clear cell renal cell carcinoma samples identifies a glycolysis signature associated with prognosis and treatment response.

Xi Tian, Yue Wang, Wenhao Xu

|Apr 02, 2021
Construction of an immune-related LncRNA signature with prognostic significance for bladder cancer.

Wen-Jie Luo, Xi Tian, Wen-Hao Xu

|Feb 24, 2021
Construction of a robust prognostic model for adult adrenocortical carcinoma: Results from bioinformatics and real-world data.

Xi Tian, Wen-Hao Xu, Aihetaimujiang Anwaier

|Jun 23, 2020
Large-scale transcriptome profiles reveal robust 20-signatures metabolic prediction models and novel role of G6PC in clear cell renal cell carcinoma.

Wen-Hao Xu, Yue Xu, Xi Tian

Pageof 1

Frequent Collaborators

4 joint publications

Wenhao Xu

3 joint publications

Dingwei Ye

2 joint publications

Wangrui Liu

2 joint publications

Aihetaimujiang Anwaier